Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis.

The Journal of antimicrobial chemotherapy - 1 Mar 2004

Rodríguez J C, Cebrián L, López M, Ruiz M, Jiménez I, Royo G

Abstract excerpt

OBJECTIVES: The mutant prevention concentration (MPC) has recently been defined to characterize the capacity for severely restricting the selection of resistant mutants during antibiotic treatment. We determined this parameter for ciprofloxacin, levofloxacin, gatifloxacin, moxifloxacin and linezolid in Mycobacterium tuberculosis clinical isolates in our setting. METHODS: We determined the antibiotic concentration...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetamides
Share to Anti-Infective Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Area Under Curve

Share to Fluoroquinolones

Share to Linezolid

Share to Mycobacterium tuberculosis

Share to Oxazolidinones

Share to Tuberculosis

Source

Identifiers

PMID: 14963069
DOI: 10.1093/jac/dkh119

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis.PMID 14963069Read ↗

Mutant prevention concentration of isoniazid, rifampicin and rifabutin against Mycobacterium tuberculosis.Semantic proximity Read ↗

Mutant prevention concentration: a new tool for choosing treatment in nontuberculous mycobacterial infections.Semantic proximity Read ↗

Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.Semantic proximity Read ↗

[Mutant prevention concentrations of fluoroquinolones for Staphylococcus aureus].Semantic proximity Read ↗

Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis.Semantic proximity Read ↗

New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach.Semantic proximity Read ↗

Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window.Semantic proximity Read ↗

[Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].Semantic proximity Read ↗

Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus.Semantic proximity Read ↗

Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.Semantic proximity Read ↗

Usefulness of various antibiotics against Mycobacterium avium-intracellulare, measured by their mutant prevention concentration.Semantic proximity Read ↗

[Resistant mutant prevention concentration of fluoroquinolones in clinical isolates of extended spectrum beta-lactamase (ESBL) producing and non-producing strains of Escherichia coli].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.